Haemonetics (HAE) EBIAT (2009 - 2026)

Haemonetics has reported EBIAT for 18 years, with the latest figure at -$20.1 million in Q1 2026.

• For the quarter ending Q1 2026, EBIAT fell 134.75% year-over-year to -$20.1 million; the trailing twelve-month figure through Mar 2026 stood at $97.3 million (down 41.97% YoY), and the FY2026 full-year result was $97.3 million, down 41.97% from the prior year.
• EBIAT for Q1 2026 stood at -$20.1 million, down from $44.7 million in the prior quarter.
• The five-year high for EBIAT was $58.0 million in Q1 2025, with the low at -$20.1 million in Q1 2026.
• Average EBIAT over 5 years is $29.5 million, with a median of $33.1 million recorded in 2022.
• Year-over-year, EBIAT soared 546.27% in 2022 and sank 134.75% in 2026.
• Tracing HAE's EBIAT over 5 years: stood at $32.9 million in 2022, then decreased by 5.17% to $31.2 million in 2023, then advanced by 20.02% to $37.5 million in 2024, then increased by 19.33% to $44.7 million in 2025, then sank by 145.03% to -$20.1 million in 2026.
• The last three EBIAT figures came in at -$20.1 million (Q1 2026), $44.7 million (Q4 2025), and $38.7 million (Q3 2025), per Business Quant data.

Peer Comparison